Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal

2743 - A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)

Date

11 Sep 2017

Session

Gastrointestinal tumours, non-colorectal

Presenters

Pascal Hammel

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

P. Hammel1, J. Bachet2, F. Portales3, L. Mineur4, J. Metges5, C. de la Fouchardiere6, C. Louvet7, F. El Hajbi8, R. Faroux9, R. Guimbaud10, D. Tougeron11, J. Volet12, T. Lecomte13, C. Tournigand14, C. Rebischung15, W. Berlier16, A. Gupta17, J. Cros1, T. André18, I. El-Hariry16

Author affiliations

  • 1 Gastroenterology, Hôpital Beaujon, 92110 - Clichy/FR
  • 2 Department Of Gastroenterology, CHU Pitié Salpetriere, 75651 - Paris/FR
  • 3 Oncologue Digestif, Institut régional du Cancer de Montpellier (ICM), Montpellier/FR
  • 4 Radiotherapy And Oncology Gi And Liver, Institut Ste Catherine, Avignon/FR
  • 5 Oncology, CHRU de Brest - Hôpital Morvan, Brest/FR
  • 6 Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 7 Medical Oncology, Institute Mutualiste Montsouris, 75014 - Paris/FR
  • 8 Oncology, Centre Oscar Lambret, Lille/FR
  • 9 Oncology, CHD Vendee - Hopital Les Oudairies, 85925 - La Roche sur Yon/FR
  • 10 Department Of Gastroenterology And Oncology, CHU Rangueil, Toulouse/FR
  • 11 Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 12 Gastroenterology, Polyclinique Courlancy, Reims/FR
  • 13 Department Of Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 14 Oncology, CHU Henri Mondor, Creteil Cedex/FR
  • 15 Oncology, GROUPE HOSPIT. MUTUALISTE DE GRENOBLE, Grenoble/FR
  • 16 Clinical, Erytech Pharma, Lyon/FR
  • 17 Clinical, Erytech Pharma, Cambridge/US
  • 18 Oncology, Hôpital Saint-Antoine, 75571 - Paris/FR
More

Resources

Abstract 2743

Background

L-asparaginase (L-ASP) hydrolyses asparagine, an amino acid essential for the survival and proliferation of cancer cells. Asparagine synthetase (ASNS) expression is believed to play a role in determining sensitivity to asparaginase treatment. Eryaspase, L-ASP encapsulated in erythrocytes, showed encouraging activity and improved safety profile compared to L-ASP in patients (pts) with relapsed ALL. This prompted us to evaluate eryaspase in combination with chemo in pancreatic cancer (PC).

Methods

This open label, multicenter phase 2b randomized study (2:1) enrolled pts with second-line metastatic PC. Pts eligible to gemcitabine or FOLFOX regimen were randomized to chemo +/- eryaspase (100 IU/Kg D3 and D17 of 4-wk regimen) until disease progression. The endpoint of the study was improvement in PFS or OS in pts with no or low ASNS (0/1) expression as determined by IHC, with a target Hazard ratio (HR) < 0.85. Secondary endpoints included OS, PFS, ORR, safety and QoL. The primary analysis took place after around 6 mo follow-up (FUP).

Results

140 pts were enrolled. The baseline characteristics were well balanced across the 2 treatment arms. The ASNS 0/1 (n = 65 and 32 in eryaspase & control arms, respectively), demonstrated a HR of 0.73 for PFS and 0.62 for OS; therefore the trial met its primary endpoint. In the entire patient population, eryaspase led to improvement of OS (median 26.1 wks) compared to control (median 19 wks); HR of 0.57 (P = 0.03). Similarly, eryaspase led to significant improvement in PFS. The treatment effect in favor of eryaspase was comparable across various prognostic indicators. Overall, treatment was well tolerated, with asthenia, nausea and vomiting, and myelosuppression being the most frequent events in both arms. Final results with additional FUP on efficacy and safety outcome measures will be provided at the meeting.

Conclusions

In pts with PC receiving second-line chemotherapy treatment, the addition of eryaspase provided significant improvement in OS and PFS, irrespective of ASNS expression levels. The role of the ASNS expression will be further investigated. Further investigation of eryaspase in PC in a P3 study is warranted.

Clinical trial identification

2013-004262-34

Legal entity responsible for the study

Erytech Pharma

Funding

Erytech Pharma

Disclosure

P. Hammel: Advisory board: Astra Zeneca; Merck Serono, Celgene, Shire, Ipsen. Corporate-sponsored research: Roche, Celgene. L. Mineur: Advisory board: Sanofi, Bayer and Roche. C. Louvet: Advisory board: Celgene and Roche. D. Tougeron: Advisory board: Sanofi, Amgen and Celgene. W. Berlier, A. Gupta: Employee pf Erytech Pharma. T. André: Advisory board: BMS, Amgen and Roche. I. El-Hariry: Employee as Chief Medical Officer, own stocks, Board of Directors: Erytech Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings